Treatment of Paediatric COVID-19 There is insufficient data exclusively for treatment of paediatric COVID-19. All recommendations are based on the outcomes of adult COVID-19 treatment. • Remdesivir; - Hospitalized children > 12 years + risk factors for severe disease + increasing need for supplemental oxygen - Hospitalized children >16 years (and all age groups) + abrupt or increasing need for supplemental oxygen • Dexamethoasone; for hospitalized children who need non-invasive ventilation, high-flow oxygen or extracorporeal membrane oxygenation • Anti-SARS-CoV-2 monoclonal antibody products; insufficient data to recommend or oppose its use • Bamlanivimab + Etesevimab OR Casirivimab + Imdevimab; for those who meet EUA criteria • Convalescent plasma; insufficient data to recommend • Baricitinib + Remdesivir; insufficient data to recommend • Tocilizumab and Sarilumab; insufficient data to recommend